ASX:FTT

Stock Analysis Report

Executive Summary

Factor Therapeutics Limited, a clinical stage biotechnology company, develops treatments for wound care and healing.

Snowflake

Fundamentals

Adequate balance sheet and overvalued.

Share Price & News

How has Factor Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

16.7%

FTT

2.0%

AU Biotechs

1.0%

AU Market


1 Year Return

-94.8%

FTT

30.6%

AU Biotechs

11.7%

AU Market

Return vs Industry: FTT underperformed the Australian Biotechs industry which returned 30.6% over the past year.

Return vs Market: FTT underperformed the Australian Market which returned 11.7% over the past year.


Shareholder returns

FTTIndustryMarket
7 Day16.7%2.0%1.0%
30 Day0%6.1%-0.2%
90 Day0%10.6%0.3%
1 Year-94.8%-94.8%32.1%30.6%18.1%11.7%
3 Year-95.0%-95.1%141.5%132.7%37.4%19.0%
5 Year-98.8%-98.9%227.8%206.5%51.7%17.6%

Price Volatility Vs. Market

How volatile is Factor Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Factor Therapeutics undervalued compared to its fair value and its price relative to the market?

1.13x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate FTT's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate FTT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: FTT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: FTT is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate FTT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: FTT is good value based on its PB Ratio (1.1x) compared to the AU Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Factor Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

12.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Factor Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Factor Therapeutics performed over the past 5 years?

7.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: FTT is unprofitable, but has reduced losses over the past 5 years at a rate of 7.8% per year.

Accelerating Growth: Unable to compare FTT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FTT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.7%).


Return on Equity

High ROE: FTT has a negative Return on Equity (-129.01%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: FTT is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: FTT is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Factor Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: FTT's short term assets (A$3.5M) exceeds its short term liabilities (A$267.5K)

Long Term Liabilities: FTT has no long term liabilities


Debt to Equity History and Analysis

Debt Level: FTT is debt free.

Reducing Debt: FTT has not had any debt for past 5 years.


Balance Sheet

Inventory Level: FTT has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if FTT's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: FTT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: FTT has less than a year of cash runway if free cash flow continues to reduce at historical rates of -3.9% each year


Next Steps

Dividend

What is Factor Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.5%markettop25%5.6%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate FTT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate FTT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if FTT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FTT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FTT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

What is the CEO of Factor Therapeutics's salary, the management and board of directors tenure and is there insider trading?

3.2yrs

Average board tenure


CEO

Factor Therapeutics has no CEO, or we have no data on them.


Board Age and Tenure

3.2yrs

Average Tenure

Experienced Board: FTT's board of directors are considered experienced (3.2 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyAU$9,95701 May 19
Pura Vida Energy NL
EntityCompany
Shares1,981,583
Max PriceAU$0.005
BuyAU$6,06521 Mar 19
Pura Vida Energy NL
EntityCompany
Shares1,500,000
Max PriceAU$0.004
BuyAU$8,08821 Mar 19
Timothy Neesham
EntityIndividual
Shares2,000,000
Max PriceAU$0.004
BuyAU$8,08821 Mar 19
David Neesham
EntityIndividual
Shares2,000,000
Max PriceAU$0.004
BuyAU$9612 Mar 19
Pura Vida Energy NL
EntityCompany
Shares24,107
Max PriceAU$0.004
BuyAU$137,63627 Feb 19
Pura Vida Energy NL
EntityCompany
Shares35,538,835
Max PriceAU$0.0039
BuyAU$14,99406 Feb 19
Timothy Neesham
EntityIndividual
Shares5,000,000
Max PriceAU$0.003
BuyAU$14,99406 Feb 19
Pamela Neesham
EntityIndividual
Shares5,000,000
Max PriceAU$0.003
BuyAU$14,99406 Feb 19
David Neesham
EntityIndividual
Shares5,000,000
Max PriceAU$0.003
BuyAU$451,14619 Nov 18
FIL Limited
EntityCompany
Shares11,278,602
Max PriceAU$0.04
SellAU$326,52916 Nov 18
Orbis Investment Management Limited
EntityCompany
Shares117,909,492
Max PriceAU$0.0084

Ownership Breakdown


Management Team

  • Melanie Farris

    Company Secretary

    • Tenure: 3.1yrs
  • Chris Behrenbruch (44yo)

    Executive Director

    • Tenure: 4yrs
    • Compensation: AU$65.54k
  • Ros Wilson

    Consultant

    • Tenure: 0.8yrs
    • Compensation: AU$520.36k

Board Members

  • Rob Kirsner

    Member of Medical Advisory Board

    • Tenure: 3.2yrs
  • David Sanders

    Director

    • Tenure: 0.6yrs
  • Keith Harding

    Member of Medical Advisory Board

    • Tenure: 3.2yrs
  • David Brookes (59yo)

    Non-Executive Director

    • Tenure: 0.5yrs
  • David Margolis

    Member of Medical Advisory Board

    • Tenure: 3.2yrs
  • Chris Behrenbruch (44yo)

    Executive Director

    • Tenure: 4yrs
    • Compensation: AU$65.54k
  • Ron Shannon

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Bruce Lane

    Director

    • Tenure: 0.6yrs

Company Information

Factor Therapeutics Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Factor Therapeutics Limited
  • Ticker: FTT
  • Exchange: ASX
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$3.650m
  • Shares outstanding: 1.04b
  • Website: https://www.factor-therapeutics.com

Location

  • Factor Therapeutics Limited
  • 66 Eagle Street
  • Level 11
  • Brisbane
  • Queensland
  • 4001
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FTTASX (Australian Securities Exchange)YesOrdinary SharesAUAUDMar 2004
1TTDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMar 2004
FTTCHIA (Chi-X Australia)YesOrdinary SharesAUAUDMar 2004
TSSH.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMar 2004

Biography

Factor Therapeutics Limited, a clinical stage biotechnology company, develops treatments for wound care and healing. The company was formerly known as Tissue Therapies Limited and changed its name to Facto ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/15 10:30
End of Day Share Price2019/10/15 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.